论文部分内容阅读
目的探讨ZEB1(zinc finger E-box binding protein 1,锌指结合蛋白1)在不同侵袭能力乳腺肿瘤组织中的表达及其与乳腺癌临床病理特征和预后的关系。方法采用免疫组化方法检测62例浸润性乳腺癌、14例导管原位癌、36例淋巴结转移癌、24例癌旁组织中ZEB1的表达,同时采用组织芯片方法检测了150例浸润性乳腺癌组织中ZEB1的表达。结果 ZEB1在乳腺浸润性癌、导管原位癌、淋巴结转移癌、癌旁组织中表达分别为17.7%、0、41.7%、4.2%。ZEB1的表达与年龄、肿瘤直径大小、ER、PR和Her2没有相关性,但在组织学类型及有淋巴结转移患者的癌组织中表达更高。浸润性小叶癌比浸润性导管癌ZEB1表达明显更高。生存分析显示ZEB1阳性组比ZEB1阴性组预后更差,生存率更低。结论 ZEB1可作为预测乳腺癌更具侵袭性和不良预后的生物标志之一,也可作为靶向治疗的潜在生物靶点。
Objective To investigate the expression of ZEB1 (zinc finger binding protein 1) in breast cancer tissues with different invasive abilities and its relationship with the clinicopathological features and prognosis of breast cancer. Methods Immunohistochemical method was used to detect the expression of ZEB1 in 62 cases of invasive breast cancer, 14 cases of ductal carcinoma in situ, 36 cases of lymph node metastasis and 24 cases of paracancerous tissues. Tissue microarray was used to detect 150 cases of invasive breast cancer ZEB1 expression in tissues. Results The expression of ZEB1 in breast invasive ductal carcinoma, ductal carcinoma in situ, lymph node metastasis and paracancer tissues was 17.7%, 0,41.7% and 4.2%, respectively. The expression of ZEB1 was not correlated with age, tumor diameter, ER, PR and Her2, but higher in histological type and in cancerous tissues with lymph node metastasis. Invasive lobular carcinoma was significantly higher than infiltrating ductal carcinoma ZEB1 expression. Survival analysis showed that ZEB1-positive group had worse prognosis and lower survival rate than ZEB1-negative group. Conclusion ZEB1 can be used as one of the biomarkers for predicting the more aggressive and poor prognosis of breast cancer. It can also be used as a potential biological target for targeted therapy.